At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you
Why is it so difficult to get funding for early stage life science technology businesses? Does the classic model of VC funding and exit by floatation or trade sale still work?
